# Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial

> **NCT07200830** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 1524 (estimated)

## Conditions studied

- Metastatic Castration-Resistant Prostate Carcinoma
- Metastatic Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Lutetium Lu 177 Vipivotide Tetraxetan
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Patient Monitoring
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Bone Scan
- **PROCEDURE:** PSMA PET Scan
- **PROCEDURE:** MRI
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT07200830
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-08
- **Primary completion:** 2034-09-09
- **Final completion:** 2034-09-09
- **Target enrollment:** 1524 (ESTIMATED)
- **Last updated:** 2025-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07200830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07200830, "Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07200830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*